SCHEMBL13465746

SCHEMBL13465746

CCCCOCCn1cc(-n2ccc(=O)c(C(=O)c3cccc(N)c3)n2)cn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.40
KMT2A Q03164 3/20 0.37
MEN1 O00255 2/20 0.37
ELANE P08246 2/20 0.35
CYP2C9 P11712 2/20 0.34
GAA P10253 2/20 0.34
ESRRA P11474 2/20 0.33
MAPT P10636 1/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
CYP19A1 P11511 1/20 0.32
ALDH1A1 P00352 3/20 0.32
CHRNB2 P17787 1/20 0.32
CHRNA4 P43681 1/20 0.32
CYP1A2 P05177 1/20 0.32
GLA P06280 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C19 P33261 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
UHRF1 Q96T88 1/20 0.32
HPGD P15428 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13449426 0.89 POLB (0.45) POLBKMT2AMEN1ELANECYP2C9
SCHEMBL13275155 0.86 POLB (0.44) POLBKMT2AMEN1CYP2C9GAA
SCHEMBL13466292 0.85 HPGD (0.47) POLBKMT2AMEN1CYP2C9GAA
SCHEMBL13465744 0.84 CYP2C9 (0.47) POLBKMT2AMEN1CYP2C9GAA
SCHEMBL2221483 0.80 POLB (0.49) POLBKMT2AMEN1CYP2C9GAA
SCHEMBL2361589 0.75 POLB (0.40) POLBKMT2AMEN1CYP2C9GAA
SCHEMBL13274726 0.74 POLB (0.42) POLBKMT2AMEN1CYP2C9GAA
SCHEMBL13274951 0.74 SMN1; SMN2 (0.42) POLBKMT2ACYP2C9GAAMAPT
SCHEMBL13449424 0.71 CYP2C9 (0.56) POLBKMT2AMEN1CYP2C9GAA
SCHEMBL2222234 0.70 POLB (0.62) POLBKMT2AMEN1CYP2C9GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120264735-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2012-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120264735-A1 TYROSINE KINASE INHIBITORS ABL1, MET, ERBB2 POLB 1954/4885KMT2A 720/4885MEN1 1349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.